15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection — RxCUI 2375136
RxNorm drug concept · Semantic clinical drug
RxCUI 2375136
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2375136
Official name15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdaratumumab-fihj 1800 MG / hyaluronidase-fihj 30,000 UNT per 15 mL Injection; daratumumab-fihj 1800 MG / hyaluronidase-fihj 30,000 UNT in 15 mL Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)24,846 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Daratumumab Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Darzalex is a type of targeted therapy called a monoclonal antibody. It works by homing in on a protein called CD38 that sits on the surface of myeloma cells. Once it locks on, it...
- What exactly is Darzalex and what is it supposed to do for my myeloma?
- No, Darzalex can't be taken at home. It's given as an IV infusion through a vein, always in a clinic or infusion center by trained healthcare staff. That's because there's a risk o...
- How will I get this medication — do I take it at home?
🕸️ Concept Web — How 15 ML daratumumab-fihj 120 MG/ML / hyaluronidase... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection
RxCUI 2375136 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 5
The active substance itself — no strength, form, or brand attached yet.
-
Daratumumab
1721947IN -
Hyaluronidase
5464IN -
Daratumumab / hyaluronidase
2372199MIN -
Daratumumab-fihj
2375130PIN -
Hyaluronidase-fihj
2375132PIN
-
Daratumumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Darzalex Faspro
2375137BN
-
Darzalex Faspro
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Daratumumab / hyaluronidase Injection
2375135SCDF -
Daratumumab-fihj / hyaluronidase-fihj Injection
2649490SCDFP -
Daratumumab / hyaluronidase Injectable Product
2375134SCDG -
Daratumumab-fihj / hyaluronidase-fihj Injectable Product
2660319SCDGP -
Daratumumab / hyaluronidase Injection [Darzalex Faspro]
2375139SBDF -
Daratumumab-fihj / hyaluronidase-fihj Injection [Darzalex Faspro]
2655021SBDFP -
Darzalex Faspro Injectable Product
2375140SBDG -
Injection
1649574DF - +1 more in this family
-
Daratumumab / hyaluronidase Injection
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Daratumumab-fihj 120 MG/ML
2375131SCDC -
Hyaluronidase-fihj 2000 UNT/ML
2375133SCDC -
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
2375141SBD -
Daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro]
2375138SBDC
-
Daratumumab-fihj 120 MG/ML
Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Daratumumab-fihj 120 MG/ML
SCDC · 2375131 -
Hyaluronidase-fihj 2000 UNT/ML
SCDC · 2375133 -
Daratumumab / hyaluronidase Injection
SCDF · 2375135 -
Daratumumab-fihj / hyaluronidase-fihj Injection
SCDFP · 2649490 -
Daratumumab / hyaluronidase Injectable Product
SCDG · 2375134 -
Daratumumab-fihj / hyaluronidase-fihj Injectable Product
SCDGP · 2660319
Brand-Name Concepts
-
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
SBD · 2375141 -
Daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML [Darzalex Faspro]
SBDC · 2375138 -
Daratumumab / hyaluronidase Injection [Darzalex Faspro]
SBDF · 2375139 -
Daratumumab-fihj / hyaluronidase-fihj Injection [Darzalex Faspro]
SBDFP · 2655021 -
Darzalex Faspro Injectable Product
SBDG · 2375140 -
Darzalex Faspro
BN · 2375137
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2375136 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 57894-0503-01 | 1 VIAL, SINGLE-DOSE in 1 BOX (57894-503-01) / 15 mL in 1 VI... | Darzalex Faspro | Janssen Biotech, Inc. | 2020-05-01 |
Observed labelers:
Janssen Biotech, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J9144 | Daratumumab, hyaluronidase | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.